These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35797625)

  • 1. Blockade of Osteoclast-Mediated Bone Resorption With a RANKL-Inhibitor Enhances Bone Formation in a Rat Spinal Fusion Model.
    Payne KA; Shaw NM; Erickson CB; Yarger P; Yu Y; Baldini T; Kleck CJ; Patel VV; Burger EL
    Spine (Phila Pa 1976); 2022 Aug; 47(16):1165-1171. PubMed ID: 35797625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.
    Roudier MP; Bain SD; Dougall WC
    Clin Exp Metastasis; 2006; 23(3-4):167-75. PubMed ID: 16912914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone.
    Song R; Gu J; Liu X; Zhu J; Wang Q; Gao Q; Zhang J; Cheng L; Tong X; Qi X; Yuan Y; Liu Z
    Int J Mol Med; 2014 Sep; 34(3):856-62. PubMed ID: 25017214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
    Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
    Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
    Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
    J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
    Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
    J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boldine isolated from Litsea cubeba inhibits bone resorption by suppressing the osteoclast differentiation in collagen-induced arthritis.
    Zhao H; Xu H; Qiao S; Lu C; Wang G; Liu M; Guo B; Tan Y; Ju D; Xiao C
    Int Immunopharmacol; 2017 Oct; 51():114-123. PubMed ID: 28826044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functions of RANKL/RANK/OPG in bone modeling and remodeling.
    Boyce BF; Xing L
    Arch Biochem Biophys; 2008 May; 473(2):139-46. PubMed ID: 18395508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overloaded Orthopedic Force Induces Condylar Subchondral Bone Absorption by Stimulating Rat Mesenchymal Stem Cells Differentiating into Osteoclasts via mTOR-Regulated
    Tian Y; Chen J; Yan X; Ren D; Liu M; Zhang Q; Zhang Q; Yuan X
    Stem Cells Dev; 2021 Jan; 30(1):29-38. PubMed ID: 33176606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.
    Kang JH; Ko HM; Moon JS; Yoo HI; Jung JY; Kim MS; Koh JT; Kim WJ; Kim SH
    J Dent Res; 2014 Nov; 93(11):1116-23. PubMed ID: 25256714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
    Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
    Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.
    Jin Q; Cirelli JA; Park CH; Sugai JV; Taba M; Kostenuik PJ; Giannobile WV
    J Periodontol; 2007 Jul; 78(7):1300-8. PubMed ID: 17608585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening.
    Aspenberg P; Agholme F; Magnusson P; Fahlgren A
    Bone; 2011 Feb; 48(2):225-30. PubMed ID: 20858557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiosteoclastic bone resorption activity of osteoprotegerin via enhanced AKT/mTOR/ULK1-mediated autophagic pathway.
    Zhao H; Sun Z; Ma Y; Song R; Yuan Y; Bian J; Gu J; Liu Z
    J Cell Physiol; 2020 Mar; 235(3):3002-3012. PubMed ID: 31535378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
    Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
    Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.